Yahoo Finance • 8 days ago
Earnings Call Insights: ACADIA Pharmaceuticals (ACAD) Q2 2025 MANAGEMENT VIEW * Catherine E. Owen Adams, CEO, stated that "Our second quarter performance reinforces the momentum we're building across all facets of our business from com... Full story
Yahoo Finance • 8 days ago
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD [https://www.chartmill.com/stock/quote/ACAD/profile]) REPORTS Q2 2025 EARNINGS: REVENUE GROWTH MEETS EXPECTATIONS, EPS BEATS ESTIMATES Acadia Pharmaceuticals Inc. released its second-quarter 2025 fi... Full story
Yahoo Finance • 8 days ago
Major earnings expected after the bell on Wednesday include: * Realty Income Corporation (O [https://seekingalpha.com/symbol/O]) * Energy Transfer LP (ET [https://seekingalpha.com/symbol/ET]) * Occidental Petroleum Corporation (OXY... Full story
Yahoo Finance • 9 days ago
September S&P 500 E-Mini futures (ESU25 [https://www.barchart.com/futures/quotes/ESU25]) are trending up +0.24% this morning as investors digested U.S. President Donald Trump’s latest tariff threats and weak economic data, while shifting t... Full story
Yahoo Finance • 10 days ago
SAN DIEGO, August 04, 2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Scott Cenci as Senior Vice President, Chief Information and Data Officer. In this role, Scott will lead Acadia’s dig... Full story
Yahoo Finance • 15 days ago
In the last week, the market has been flat, but it is up 16% over the past year with earnings forecast to grow by 15% annually. In this context of steady growth, identifying high-growth tech stocks involves looking for companies that are w... Full story
Yahoo Finance • 16 days ago
Over the last 7 days, the United States market has remained flat, yet it has shown a robust performance with a 17% increase over the past year and earnings forecasted to grow by 15% annually. In this environment of steady growth, identifyi... Full story
Yahoo Finance • 21 days ago
Investors looking for growth opportunities at fair prices often consider the "Affordable Growth" strategy, which focuses on companies with strong growth potential but without extreme overvaluation. This method selects stocks with a growth... Full story
Yahoo Finance • last month
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company specializing in central nervous system (CNS) disorders, is navigating a critical phase of growth and expansion. With a robust product portfolio and an ambitious pipeli... Full story
Yahoo Finance • 2 months ago
Investing.com - BMO Capital reiterated its Outperform rating and $28.00 price target on Acadia Pharmaceuticals (NASDAQ:ACAD), currently trading at $22.50 with a market capitalization of $3.77 billion, following the company’s research and d... Full story
Yahoo Finance • 2 months ago
Investing.com - Canaccord Genuity reiterated its Buy rating and $32.00 price target on Acadia Pharmaceuticals (NASDAQ:ACAD) following the company’s inaugural R&D Day held Wednesday. The research firm expressed increased conviction that th... Full story
Yahoo Finance • 2 months ago
[manhattan office building] franckreporter/iStock via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices ne... Full story
Yahoo Finance • 2 months ago
Macquarie initiated coverage on Neuren Pharmaceuticals Ltd (ASX:NEU) with an outperform rating and a price target of AUD18.60, according to a research note released Wednesday. The firm highlighted Neuren’s partnership with Acadia as a key... Full story
Yahoo Finance • 2 months ago
[Male Judge In A Courtroom Typing On Laptop] AndreyPopov/iStock via Getty Images * Acadia Pharmaceuticals (NASDAQ:ACAD [https://seekingalpha.com/symbol/ACAD]) said on Monday that the U.S. Court of Appeals upheld a December 2023 ruling,... Full story
Yahoo Finance • 3 months ago
SAN DIEGO, May 27, 2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise. In this role Allyson will be joining Acad... Full story
Yahoo Finance • 3 months ago
We recently published a list of 10 Surprising Stocks That Skyrocketed Today. In this article, we are going to take a look at where ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stands against other Friday’s top performers. The stock market fi... Full story
Yahoo Finance • 3 months ago
Oppenheimer raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $19 from $17 and keeps a Perform rating on the shares. The firm sees the Delaware court’s verdict in favor of Acadia as consistent with its expectations for Nup... Full story
Yahoo Finance • 3 months ago
BMO Capital analyst Evan Seigerman notes that a U.S. district court issued a ruling in favor of Acadia Pharmaceuticals (ACAD) in their Nuplazid patent infringement lawsuit with Aurobindo, confirming today that Aurobindo infringed on claims... Full story
Yahoo Finance • 6 months ago
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shareholders are probably feeling a little disappointed, since its shares fell 4.7% to US$19.34 in the week after its latest annual results. Revenues were US$958m, approximately in line with whatth... Full story
Yahoo Finance • last year
SAN DIEGO, August 07, 2024--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference on Wednesday, August 14, 2024 at 10:... Full story